The present invention relates to a farnesoid X agonist, and discloses a compound represented by the following formula represented in the specification. According to the present invention, the compoundOBN-DAS has agonistic effect on FXR, has the EC50 value comparable to the EC50 value of obeticholic acid, can significantly reduce the ALP level and the TBIL level in the serum of biliary cirrhosis rat models caused by bile duct ligation, can significantly improve the liver fibrosis score, has the PBC treatment effect comparable to the PBC treatment effect of obeticholic acid, can significantly decrease the ALT level and the AST level in the serum of MCD-induced NASH model rats and significantly improve the liver pathological NASH scores, has the NASH treatment effect comparable to the NASH treatment effect of obeticholic acid, and further has the significantly-reduced incidence of itching adverse reaction compared to obeticholic acid.